Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain
Open Access
- 17 September 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (12) , 1402-1406
Abstract
Altered mitochondrial function occurs in sickle cell disease (SCD), due in part to low nitric oxide (NO) bioavailability. Arginine, the substrate for NO production, becomes acutely deficient in SCD patients with vaso-occlusive pain episodes (VOE). To determine if arginine improves mitochondrial function, 12 children with SCD-VOE (13.6 ± 3 years; 67% male; 75% hemoglobin-SS) were randomized to 1 of 3 arginine doses: (1) 100 mg/kg IV 3 times/day (TID); (2) loading dose (200 mg/kg) then 100 mg/kg TID; or (3) loading dose (200 mg/kg) followed by continuous infusion (300 mg/kg per day) until discharge. Platelet-rich plasma mitochondrial activity, protein expression, and protein-carbonyls were measured from emergency department (ED) presentation vs discharge. All VOE subjects at ED presentation had significantly decreased complex-V activity compared to a steady-state cohort. Notably, complex-V activity was increased at discharge in subjects from all 3 arginine-dosing schemes; greatest increase occurred with a loading dose (P < .001). Although complex-IV and citrate synthase activities were similar in VOE platelets vs steady state, enzyme activities were significantly increased in VOE subjects after arginine-loading dose treatment. Arginine also decreased protein-carbonyl levels across all treatment doses (P < .01), suggesting a decrease in oxidative stress. Arginine therapy increases mitochondrial activity and reduces oxidative stress in children with SCD/VOE. This trial was registered at www.clinicaltrials.gov as #NCT02536170.Keywords
This publication has 34 references indexed in Scilit:
- Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex INature Medicine, 2013
- A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodesHaematologica, 2013
- Arginases and arginine deficiency syndromesCurrent Opinion in Clinical Nutrition and Metabolic Care, 2012
- Global arginine bioavailability in Tanzanian sickle cell anaemia patients at steady‐state: a nested case control study of deaths versus survivorsBritish Journal of Haematology, 2011
- The burden of emergency department use for sickle‐cell disease: An analysis of the national emergency department sample databaseAmerican Journal of Hematology, 2010
- Cardioprotection by metabolic shut-down and gradual wake-upJournal of Molecular and Cellular Cardiology, 2009
- Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stressAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Protective effect of arginine on oxidative stress in transgenic sickle mouse modelsFree Radical Biology and Medicine, 2006
- Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailabilityBlood, 2006
- Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxideFEBS Letters, 1994